AIM Vaccine Co., Ltd.（06660.HK）价格

AIM Vaccine Co., Ltd. engages in biological vaccine technology development, technology transfer, and technical services. The company is headquartered in Beijing, Beijing and currently employs 1,493 full-time employees. The company went IPO on 2022-10-06. The firm's commercialized products mainly include recombinant HBV vaccine, freeze dried human rabies vaccine, inactivated HAV vaccine, mumps vaccine, bivalent inactivated HFRS vaccine and Group A, C, Y and W135 MPSV. The firm's vaccine products under development include 13-Valent Pneumonia Conjugate Vaccine, 24-Valent Pneumonia Conjugate Vaccine, quadrivalent influenza virus vaccine, iterative serum-free rabies vaccine, mRNA shingles/herpes zoster vaccine, Iterative mRNA rabies vaccine, mRNA respiratory syncytial virus vaccine, novel-process highly-effective human diploid rabies vaccine, and others.